Debadyuti Ghosh

Debadyuti Ghosh


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
JLJasmim Leal
Jasmim Leal
HSHugh D.C. Smyth
Hugh D.C. Smyth
DGDebadyuti Ghosh
Debadyuti Ghosh
Mucus is a selective barrier to particles and molecules, preventing penetration to the epithelial surface of mucosal tissues. Significant advances in transmucosal drug delivery have recently been made and have emphasized that an understanding of the basic structure, viscoelastic properties, and interactions of mucus is of great value in the design of efficient drug delivery systems. Mucins, the primary non-aqueous component of mucus, are polymers carrying a complex and heterogeneous structure with domains that undergo a variety of molecular interactions, such as hydrophilic/hydrophobic, hydrogen bonds and electrostatic interactions. These properties are directly relevant to the numerous mucin-associated diseases, as well as delivering drugs across the mucus barrier. Therefore, in this review we discuss regional differences in mucus composition, mucus physicochemical properties, such as pore size, viscoelasticity, pH, and ionic strength. These factors are also discussed with respect to changes in mucus properties as a function of disease state. Collectively, the review seeks to provide a state of the art roadmap for researchers who must contend with this critical barrier to drug delivery.

30 October 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HZHairui Zhang
Hairui Zhang
JLJasmim Leal
Jasmim Leal
MSMelissa R. Soto
Melissa R. Soto
Hugh D.C. SmythHugh D.C. Smyth
Hugh D.C. Smyth
DGDebadyuti Ghosh
Debadyuti Ghosh
Messenger RNA is a class of promising nucleic acid therapeutics to treat a variety of diseases, including genetic diseases. The development of a stable and efficacious mRNA pulmonary delivery system would enable high therapeutic concentrations locally in the lungs to improve efficacy and limit potential toxicities. In this study, we employed a Design of Experiments (DOE) strategy to screen a library of lipid nanoparticle compositions to identify formulations possessing high potency both before and after aerosolization. Lipid nanoparticles (LNPs) showed stable physicochemical properties for at least 14 days of storage at 4 °C, and most formulations exhibited high encapsulation efficiencies greater than 80%. Generally, upon nebulization, LNP formulations showed increased particle size and decreased encapsulation efficiencies. An increasing molar ratio of poly-(ethylene) glycol (PEG)-lipid significantly decreased size but also intracellular protein expression of mRNA. We identified four formulations possessing higher intracellular protein expression ability in vitro even after aerosolization which were then assessed in in vivo studies. It was found that luciferase protein was predominately expressed in the mouse lung for the four lead formulations before and after nebulization. This study demonstrated that LNPs hold promise to be applied for aerosolization-mediated pulmonary mRNA delivery.

12 December 2017 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
DGDebadyuti Ghosh
Debadyuti Ghosh
XPXiujuan Peng
Xiujuan Peng
JLJasmim Leal
Jasmim Leal
RMRashmi P. Mohanty
Rashmi P. Mohanty

1 September 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
YZYajie Zhang
Yajie Zhang
HZHairui Zhang
Hairui Zhang
DGDebadyuti Ghosh
Debadyuti Ghosh
Robert Williams IIIRobert Williams III
Robert Williams III
How prevalent are peptide therapeutic products? How innovative are the formulations used to deliver peptides? This review provides a critical analysis of therapeutic peptide products and the formulations approved by the United States Food and Drug administration (FDA), the European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). This review also provides an in-depth analysis of dosage forms and administration routes for delivering peptide therapeutics, including injectables, oral dosage forms, and other routes of administration. We discuss the function of excipients in parenteral formulations in detail, since most peptide therapeutics are parenterally administered. We provide case studies of alternate delivery routes and dosage forms. Based on our analysis, therapeutic peptides administered as injectables remain the most commonly used dosage forms, particularly in the form of subcutaneous, intravenous, or intramuscular injections. In addition, therapeutic peptides are formulated to achieve prolonged release, often through the use of polymer carriers. The limited number of oral therapeutic peptide products and their poor absorption and subsequent low bioavailability indicate a need for new technologies to broaden the formulation design space. Therapeutic peptide products may also be delivered through other administration routes, including intranasal, implant, and sublingual routes. Therefore, an in-depth understanding of how therapeutic peptides are now formulated and administered is essential to improve peptide delivery, improve patient compliance, and reduce the healthcare burden for these crucial therapeutic agents.

31 March 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
JLJasmim Leal
Jasmim Leal
XPXiujuan Peng
Xiujuan Peng
XLXinquan Liu
Xinquan Liu
DADhivya Arasappan
Dhivya Arasappan
DWDennis C. Wylie
Dennis C. Wylie
DGDebadyuti Ghosh
Debadyuti Ghosh

1 February 2018 in Journal of Virological Methods
Verified
Journal Article
Closed access
XPXiujuan Peng
Xiujuan Peng
ANAlex Nguyen
Alex Nguyen
DGDebadyuti Ghosh
Debadyuti Ghosh